{"id":17727,"date":"2015-09-17T00:00:00","date_gmt":"2015-09-17T00:00:00","guid":{"rendered":"https:\/\/cadca1stg.wpengine.com\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/"},"modified":"2015-09-17T00:00:00","modified_gmt":"2015-09-17T00:00:00","slug":"fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products","status":"publish","type":"resource","link":"https:\/\/www.cadca.org\/es\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/","title":{"rendered":"La FDA emite \u00f3rdenes que detendr\u00e1n la venta y distribuci\u00f3n en EE. UU. de cuatro productos de cigarrillos de RJ Reynolds Tobacco Company"},"content":{"rendered":"<p>Esta semana, la Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. emiti\u00f3 \u00f3rdenes que detendr\u00e1n la venta y distribuci\u00f3n de cuatro productos de cigarrillos actualmente comercializados por RJ Reynolds Tobacco Company, incluida su marca Camel Crush Bold, porque las presentaciones de la compa\u00f1\u00eda para estos productos no cumpl\u00edan con los requisitos establecidos. en la Ley Federal de Alimentos, Medicamentos y Cosm\u00e9ticos (Ley FD&amp;C).<\/p>\n<p>La evaluaci\u00f3n de la FDA encontr\u00f3 que los cigarrillos Camel Crush Bold, Pall Mall Deep Set Recessed Filter, Pall Mall Deep Set Recessed Filter Menthol y Vantage Tech 13 no eran sustancialmente equivalentes (NSE) a sus respectivos productos \u201cpredicados\u201d (es decir, productos que se comercializaban a partir del 15 de febrero de 2007) seg\u00fan lo identificado por el fabricante. M\u00e1s espec\u00edficamente, la agencia concluy\u00f3 que los productos tienen caracter\u00edsticas diferentes a las de los productos originales y que el fabricante no pudo demostrar que los nuevos productos no plantean cuestiones de salud p\u00fablica diferentes en comparaci\u00f3n con ellos. En consecuencia, en este momento, estos productos ya no pueden venderse, distribuirse, importarse ni comercializarse en el comercio interestatal.<\/p>\n<p>&quot;Estas decisiones se basaron en una revisi\u00f3n rigurosa con base cient\u00edfica dise\u00f1ada para proteger al p\u00fablico de los da\u00f1os causados por el consumo de tabaco&quot;, dijo Mitch Zeller, JD, director del Centro de Productos de Tabaco de la FDA, en un comunicado de prensa. &quot;La agencia continuar\u00e1 revisando las presentaciones de productos y ejerciendo su autoridad legal y su deber de protecci\u00f3n al consumidor para retirar productos del mercado cuando no cumplan con los requisitos de salud p\u00fablica establecidos por la ley&quot;.<\/p>\n<p>Los productos que recibieron pedidos de NSE ingresaron al mercado durante un per\u00edodo provisional establecido por la Ley de Control del Tabaco y Prevenci\u00f3n del Tabaquismo Familiar de 2009. Como parte del per\u00edodo provisional, la empresa tuvo que presentar una solicitud de equivalencia sustancial (SE) a la FDA antes del 22 de marzo. de 2011, para que los productos permanezcan en el mercado. La FDA revisa las presentaciones de productos bajo esta v\u00eda para determinar si el producto es sustancialmente equivalente a un producto predicado v\u00e1lido. Entre otras razones, si una empresa no proporciona la informaci\u00f3n necesaria para demostrar que su producto es sustancialmente equivalente a un producto predicado v\u00e1lido, la FDA tiene la autoridad para encontrar un producto que no sea sustancialmente equivalente.<\/p>\n<p>La base cient\u00edfica de estas cuatro decisiones incluye la falta de demostraci\u00f3n de que el aumento de la producci\u00f3n de componentes da\u00f1inos o potencialmente da\u00f1inos, los niveles m\u00e1s altos de mentol y\/o la adici\u00f3n de nuevos ingredientes en los productos actualmente comercializados<strong>\u2013\u00a0<\/strong>en comparaci\u00f3n con los productos predicados\u00a0<strong>\u2013\u00a0<\/strong>no plantean cuestiones diferentes de salud p\u00fablica.<\/p>\n<p>En el caso de Camel Crush Bold, el hecho de no demostrar que la adici\u00f3n de una c\u00e1psula de mentol en el filtro no afect\u00f3 la percepci\u00f3n y el uso del consumidor tambi\u00e9n contribuy\u00f3 a la decisi\u00f3n.<\/p>\n<p>Cuando la FDA emite una orden NSE, el producto de tabaco en el inventario, incluso en una tienda minorista, queda adulterado y mal etiquetado. Como resultado, es ilegal vender o distribuir el producto en el comercio interestatal, o vender o distribuir el producto recibido del comercio interestatal. Hacerlo puede dar lugar a que la FDA inicie medidas coercitivas, incluida la incautaci\u00f3n, sin previo aviso.<\/p>\n<p>Al reconocer que los minoristas pueden tener opciones limitadas para deshacerse de los productos en sus inventarios actuales, la FDA no tiene la intenci\u00f3n de tomar medidas coercitivas durante 30 d\u00edas sobre productos comprados anteriormente que un minorista tiene en su inventario. Esta pol\u00edtica se describe con m\u00e1s detalle en una gu\u00eda finalizada recientemente. Es importante destacar que la pol\u00edtica no se aplica al inventario comprado por minoristas despu\u00e9s de la fecha del pedido. Se anima a los minoristas a ponerse en contacto con su proveedor o fabricante para analizar posibles opciones para los inventarios existentes en ubicaciones minoristas espec\u00edficas.<\/p>\n<p>El incumplimiento de las leyes federales sobre productos de tabaco puede dar lugar a que la FDA inicie acciones adicionales sin previo aviso, incluidas, entre otras, sanciones monetarias civiles, \u00f3rdenes de prohibici\u00f3n de venta de tabaco, procesos penales, incautaciones y\/o medidas cautelares.<\/p>\n<p>Los consumidores y otras partes interesadas pueden informar una posible violaci\u00f3n de la Ley FD&amp;C relacionada con el tabaco, incluida la venta o distribuci\u00f3n continua de los cuatro productos en los Estados Unidos, utilizando el formulario de la FDA.\u00a0<a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/ptvr\/index.cfm\" target=\"_blank\" rel=\"noopener\">Formulario de informe de posible infracci\u00f3n de productos de tabaco<\/a>.<\/p>\n<p><strong>VER TAMBI\u00c9N: <\/strong><\/p>\n<p><a href=\"https:\/\/www.geohealthequity.org\/\" target=\"_blank\" rel=\"noopener\">Kit de herramientas en l\u00ednea para prevenir el consumo de tabaco de CADCA<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>This week, the U.S. Food and Drug Administration issued orders that will stop the further sale and distribution of four<\/p>","protected":false},"author":23,"featured_media":0,"template":"","resource_type":[281],"drug_specific_issues":[296],"action_to_do":[],"class_list":["post-17727","resource","type-resource","status-publish","hentry","resource_type-coalitions-online","drug_specific_issues-tobacco"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cadca.org\/es\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA\" \/>\n<meta property=\"og:description\" content=\"This week, the U.S. Food and Drug Administration issued orders that will stop the further sale and distribution of four\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cadca.org\/es\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/\" \/>\n<meta property=\"og:site_name\" content=\"CADCA\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/cadca-member-of-logo1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"880\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\\\/\",\"url\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\\\/\",\"name\":\"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cadca.org\\\/#website\"},\"datePublished\":\"2015-09-17T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/resource\\\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cadca.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cadca.org\\\/#website\",\"url\":\"https:\\\/\\\/www.cadca.org\\\/\",\"name\":\"CADCA\",\"description\":\"The Premier Prevention Association\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cadca.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cadca.org\/es\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/","og_locale":"es_ES","og_type":"article","og_title":"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA","og_description":"This week, the U.S. Food and Drug Administration issued orders that will stop the further sale and distribution of four","og_url":"https:\/\/www.cadca.org\/es\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/","og_site_name":"CADCA","og_image":[{"width":880,"height":500,"url":"https:\/\/www.cadca.org\/wp-content\/uploads\/2022\/03\/cadca-member-of-logo1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cadca.org\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/","url":"https:\/\/www.cadca.org\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/","name":"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products | CADCA","isPartOf":{"@id":"https:\/\/www.cadca.org\/#website"},"datePublished":"2015-09-17T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.cadca.org\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cadca.org\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.cadca.org\/resource\/fda-issues-orders-that-will-stop-further-u-s-sale-and-distribution-of-four-r-j-reynolds-tobacco-company-cigarette-products\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cadca.org\/"},{"@type":"ListItem","position":2,"name":"FDA Issues Orders that will Stop Further U.S. Sale and Distribution of Four R.J. Reynolds Tobacco Company Cigarette Products"}]},{"@type":"WebSite","@id":"https:\/\/www.cadca.org\/#website","url":"https:\/\/www.cadca.org\/","name":"CADCA","description":"The Premier Prevention Association","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cadca.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/resource\/17727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/resource"}],"about":[{"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/types\/resource"}],"author":[{"embeddable":true,"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/users\/23"}],"version-history":[{"count":0,"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/resource\/17727\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/media?parent=17727"}],"wp:term":[{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/resource_type?post=17727"},{"taxonomy":"drug_specific_issues","embeddable":true,"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/drug_specific_issues?post=17727"},{"taxonomy":"action_to_do","embeddable":true,"href":"https:\/\/www.cadca.org\/es\/wp-json\/wp\/v2\/action_to_do?post=17727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}